1.UK cancer incidence statistics for males, 2003. Cancer Research UK website (http://info.cancerresearchuk.org/cancerstats/incidence/males/?a=5441)
February 2007.

2.Royal College of Radiologists Clinical Oncology Information Network (COIN) & British Association of Urological Surgeons (BAUS) Guidelines on the management of prostate cancer. Clinical Oncology 1999; 11:55-81.

3.Improving Outcomes in Urological Cancers: The Manual (2002) National Institute for Health and Clinical Excellence (NICE).

4.McWilliam LJ, Roberts ISD, Davies DR  Problems in grading and staging prostatic carcinoma. Current Diagnostic Pthology, 2002 8, 65-75.

5.Kirby RS et al. Fast Facts; Prostate cancer, 2001. Health Press.

6.Zeliadt AW et al. Why do men choose one treatment over another? A review of patient decision making for localised prostate cancer. Cancer 2006; 106:1865-74.

7.Parker C Active surveillance: towards a new paradigm in the management of early prostate cancer, The Lancet Oncology 2004, Feb;5:102-106.

8.Johansson JE et al. Natural History of Early, Localized Prostate Cancer. JAMA June 9, 2004; 291(22):2713-9.

9.Albertsen PC et al. Gleason score predicted mortality rate to 20 years for untreated early prostate cancer EBM October 2005; Vol.10.

10.Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO Fifteen year survival in prostate cancer. A prospective, population based study in Sweden. JAMA 1997; 277(6):467-71.

11.Bill-Axelson A et al. Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer. NEJM 2005;352:1977-84.

12.Steineck G et al. Quality of life after radical prostatectomy or watchful waiting.

13.Harris RP et al. Screening for prostate cancer. Systematic Evidence Review no.16. Rockville, MD Agency for Healthcare Research and Quality, 2001.

14.Wirth MP et al. Bicalutamide 150mg in addition to standard care in patients with localized or locally prostate cancer: results from the second analysis of the early prostate cancer program at median follow-up of 5.4 years. J Urol 2004;172:1865-70.

15.Belldegrun A, Kirby RS, Oliver T New Perspectives in Prostate Cancer, 1999. Isis Medical Media.

16.Nilsson S et al. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol 2004 43;4:316-81.

17.Torricelli P, Idanza M, De Santis M, Pollastri C. et al. Magnetic resonance with endorectal coil in the local staging of prostatic carcinoma: comparison with histological macrosection in 40 cases. Radiological Medicine 1999; 97(6):491-498.

18. Robinson JW et al. Meta-analysis of rates or erectile function after treatment of lacalised prostate carcinoma. Int J Radiat Oncol Biol Phys 2002;54:1063-8.

19. Kirby RS Management of carcinoma of the prostate. Hospital Medicine 1999;60(10):702-703.

20. Zietman AL et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled controlled trial. JAMA 2005;294:1233-9.

21. Zelefsky MJ et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiotherapy & Oncology 2000;55(3):241-9.

22. Ash D, Bottomley DM, Carey BM Prostate brachytherapy review, Prostate Cancer and Prostatic Disease 1998;1:185-188.

23. Dearnaley DP et al. Comparison of radiation side effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999;353(9149):267-72.

24. Ohebshalom M et al. The efficacy of sildenafil citrate following radiation therapy for prostate cancer: temporal considerations. J Urol 2005 Jul;174(1):258-62; discussion 262.

25. Kedia S et al. Treatment of erectile dysfunction with sildenafil citrate after radiation therapy for prostate cancer. Urology 1999;54(2):308—312.

26. Zelefsky MJ et al. Efficacy of oral sildenafil for patients with erectile dysfunction after radiotherapy for carcinoma of the prostate. Urology 1999;53(4):775-778.

27. Schiff JD et al. Early use of a phosphodiesterase inhibitor after brachytherapy restores and preserves erectile function. BJU Int. 2006 Dec;98(6):1255-8.

28. Montorsi F McCullough A Efficacy of sildenafil citrate in men with erectile dysfunction following radical prostatectomy: a systematic review of clinical data. J Sex Med 2005 Sep;2(5):658-67.

29. Raina R et al. Long-term effect of sildenafil citrate on erectile dysfunction after radical prostatectomy: 3-year follow-up. Urology 2003 Jul;62(1):110-5.

30. Casodex 150 mg (Bicalutamide) - No longer indicated for treatment of localised Prostate Cancer. Department of Health (2003) www.info.doh.gov.uk/doh/embroadcast.nsf/vwDiscussionAll/9555EBCBA4EA459480256DCD0052AD59 [accessed 16 February 2007].

31. Soloway MS et al. Randomised prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer; the Lupron Depot Neo-Adjuvant Prostate Cancer Study Group. Journal of Urology 1995;154:424-428.

32. Goldenberg SL et al. Randomised, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localised prostate cancer. Canadian Urologic Oncology Group. Journal of Urology 1996;156:873-877.

33. Montironi R et al. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer: Initial results of the Italian PROSIT study. Pathology, Research and Practice 1999;195(4):201-208.

34. Gleave M, La Bianca S, Goldenberg SL Neoadjuvant hormonal therapy prior to radical prostatectomy: promises and pitfalls. Prostate cancer and Prostatic Disease 2000;7:136-144.

35. Klotz LH et al. Long-term follow-up of a randomised trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. Journal of Urology 2003 Sept;170(3):791-4.

36. Homma Y et al. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: five-year results. Int J Urol 2004;11:295-303.

37. Hummel S et al. Clinical and cost effectiveness of new emerging technologies for early localised prostate cancer: a systematic review. Health Technol Assess 2003;7:33.

38. DiAmico AV et al. 6-month androgen suppression plus radiation therapy versus radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004;292:821-7.

39. Laverdiere J et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localised prostate cancer. International Journal Of Radiation Oncology, Biology, Physics 1997;37(2):247-252.

40. Roach M et al. Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 2000; 47:617.

41. Crook J et al. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2004 Sep 1;60(1):15-23.

42. Overview of treatment for early prostate cancer. UpToDate online website (www.uptodate.com) May 2007.

43. Muschter R Photodynamic therapy: a new approach to prostate cancer. Curr Urol Rep. 2003 June;4(3):221-8.

44. Thuroff S et al. High-intensity focused ultrasound and localized prostate cancer efficacy results from the European multicentric study. Journal of Endourology, 2003 Oct;17(8):673-7.

45. Heidenreich A et al. Guidelines on prostate cancer. European Association Urology (2007). www.uroweb.org